We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.27%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$7.23B
AUM Growth
+$298M
(+4.3%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
2.07%
Top 10 Holdings %
Top 10 Hldgs %
15.39%
Holding
1,100
New
151
Increased
415
Reduced
333
Closed
164
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$40.6M |
| 2 |
Autodesk
ADSK
|
+$38.8M |
| 3 |
Intuit
INTU
|
+$37.1M |
| 4 |
Ecolab
ECL
|
+$35.6M |
| 5 |
Coca-Cola
KO
|
+$35.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$51.9M |
| 2 |
EOG Resources
EOG
|
+$33.8M |
| 3 |
DATA
Tableau Software, Inc.
DATA
|
+$32M |
| 4 |
Microsoft
MSFT
|
+$29.8M |
| 5 |
Ford
F
|
+$29.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.67% |
| 2 | Financials | 17.68% |
| 3 | Consumer Discretionary | 13.74% |
| 4 | Industrials | 11.53% |
| 5 | Healthcare | 11.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Norfolk Southern
NSC
$78.8B
| $9.36M | 0.13% |
46,930
+44,460
| +1,800% | +$8.82M |
|
202
Alkermes
ALKS
$8.82B
| $9.34M | 0.13% |
414,522
-179,184
| -30% | -$4.91M |
|
203
Stride
LRN
$3.69B
| $9.33M | 0.13% |
306,781
+50,338
| +20% | +$1.62M |
|
204
Ryder
R
$10.3B
| $9.14M | 0.13% |
156,817
-57,040
| -27% | -$3.39M |
|
205
ONE Gas
OGS
$5.05B
| $9.13M | 0.13% |
101,054
+12,090
| +14% | +$1.07M |
|
206
World Kinect Corp
WKC
$1.96B
| $9.1M | 0.13% |
253,138
-135,719
| -35% | -$4.26M |
|
207
Halozyme
HALO
$9.72B
| $9.1M | 0.13% |
529,598
+68,420
| +15% | +$1.1M |
|
208
BioMarin Pharmaceuticals
BMRN
$11.5B
| $8.99M | 0.12% |
104,970
+41,856
| +66% | +$3.58M |
|
|
FLOW
209
DELISTED
SPX FLOW, Inc.
FLOW
| $8.99M | 0.12% |
214,717
+24,360
| +13% | +$901K |
|
|
PRAH
210
DELISTED
PRA Health Sciences, Inc.
PRAH
| $8.97M | 0.12% |
90,471
+20,590
| +29% | +$1.97M |
|
211
JB Hunt Transport Services
JBHT
$27.1B
| $8.96M | 0.12% |
97,985
-88,244
| -47% | -$8.33M |
|
|
MASI
212
DELISTED
Masimo
MASI
| $8.9M | 0.12% |
59,836
-650
| -1% | -$89.2K |
|
213
Extreme Networks
EXTR
$3.86B
| $8.9M | 0.12% |
1,374,968
+371,500
| +37% | +$2.45M |
|
214
Huntsman Corp
HUN
$2.24B
| $8.88M | 0.12% |
434,185
+25,480
| +6% | +$535K |
|
215
Progressive
PGR
$124B
| $8.85M | 0.12% |
110,670
-288,560
| -72% | -$22.3M |
|
|
IPHI
216
DELISTED
INPHI CORPORATION
IPHI
| $8.76M | 0.12% |
174,906
-10,499
| -6% | -$489K |
|
217
SiriusPoint
SPNT
$2.98B
| $8.75M | 0.12% |
847,943
+32,130
| +4% | +$344K |
|
218
NMI Holdings
NMIH
$3.25B
| $8.73M | 0.12% |
307,644
+10,220
| +3% | +$285K |
|
219
Teradyne
TER
$54.8B
| $8.72M | 0.12% |
182,050
-23,880
| -12% | -$1.08M |
|
220
Orthofix Medical
OFIX
$455M
| $8.7M | 0.12% |
164,444
+10,690
| +7% | +$569K |
|
221
NETSCOUT
NTCT
$2.86B
| $8.66M | 0.12% |
341,142
-7,880
| -2% | -$212K |
|
222
Post Holdings
POST
$4.12B
| $8.66M | 0.12% |
127,221
+5,256
| +4% | +$369K |
|
223
Astronics
ATRO
$3.45B
| $8.62M | 0.12% |
257,168
+3,900
| +2% | +$123K |
|
224
Cabot Corp
CBT
$4.65B
| $8.6M | 0.12% |
180,238
-48,609
| -21% | -$2.19M |
|
|
VISN
225
Vistance Networks Inc
VISN
$2.66B
| $8.54M | 0.12% |
543,027
+42,990
| +9% | +$873K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2019 Portfolio in Review
As of Q2 2019, Jacobs Levy Equity Management held 1,100 positions worth $7.23B, up 4.3% from $6.93B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Jacobs Levy Equity Management's Q2 2019 filing shows 151 new, 415 increased, 333 reduced and 164 closed positions. Its largest new stake was Biogen: 175,817 shares worth $41.1M. The largest sale was Allergan plc, an estimated $51.9M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q2 2019 buy was Biogen: 175,817 shares worth $41.1M.
- Jacobs Levy Equity Management added most to Ecolab in Q2 2019, an estimated $35.6M increase.
- Jacobs Levy Equity Management's biggest Q2 2019 reduction was EOG Resources, cutting an estimated $33.8M.
- Jacobs Levy Equity Management fully exited Allergan plc in Q2 2019, selling an estimated $51.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 15% of its $7.23B portfolio in Q2 2019.
- Jacobs Levy Equity Management opened 151 new positions and closed 164 in Q2 2019.
- Jacobs Levy Equity Management's portfolio value rose 4.3% quarter-over-quarter to $7.23B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2019, filed 13 Aug 2019.